{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    9,
    14,
    22,
    33,
    34,
    36,
    38,
    39,
    40,
    45,
    46,
    47,
    50,
    51,
    54
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Dose Selection Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.9.1",
        "sectionTitle": "Evaluation of volume status and investigational product (IP) dose reduction/interruption",
        "description": "Reference for details on pharmacodynamics effects and dose selection"
      },
      {
        "id": "ref_2",
        "name": "ePRO Exclusion Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1.11.5",
        "sectionTitle": "Patient exclusion from the ePRO assessments",
        "description": "Reference for details regarding patient exclusion from ePRO assessments under certain circumstances"
      },
      {
        "id": "ref_3",
        "name": "Withdrawal Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.4",
        "sectionTitle": "Procedures for handling incorrectly enrolled or randomised patients",
        "description": "Reference for procedures regarding withdrawal of incorrectly enrolled patients"
      },
      {
        "id": "ref_4",
        "name": "Eligibility Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3",
        "sectionTitle": "PATIENT SELECTION, ENROLMENT, RANDOMISATION, RESTRICTIONS, DISCONTINUATION AND WITHDRAWAL",
        "description": "Reference to determine patient eligibility"
      },
      {
        "id": "ref_5",
        "name": "Concomitant Medication Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.7",
        "sectionTitle": "Recording of concomitant medication",
        "description": "Reference for restricted concomitant medications"
      },
      {
        "id": "ref_6",
        "name": "Discontinuation Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.9.3",
        "sectionTitle": "Procedures for discontinuation of a patient from investigational product (IP)",
        "description": "Reference for procedures following IP discontinuation"
      },
      {
        "id": "ref_7",
        "name": "Stratification Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.5.1",
        "sectionTitle": "Stratification and capping",
        "description": "Reference for stratification and capping purposes in IxRS"
      },
      {
        "id": "ref_8",
        "name": "Appendix Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix B",
        "sectionTitle": "International Airline Transportation Association (IATA) 6.2 Guidance Document",
        "description": "Reference for specified blood-borne diseases"
      },
      {
        "id": "ref_9",
        "name": "Table Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 2",
        "sectionTitle": "Laboratory variables",
        "description": "Reference for laboratory samples and central laboratory specifications"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Patients who cannot complete the electronic patient reported outcome (ePRO) assessments can still participate in the study",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "3.2 Exclusion criteria",
        "pageNumber": 34
      },
      {
        "id": "annot_2",
        "text": "After stopping IP the investigator should ensure that the patient is treated according to standard clinical practice and ascertain there is a proper medical follow-up plan in place",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "4.2.7 Study Closure Visit (SCV)",
        "pageNumber": 52
      },
      {
        "id": "annot_3",
        "text": "Failure to meet the criteria for NT-proBNP is expected to be the main reason for screen failure in this study.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "4.1.1 Visit 1, Enrolment",
        "pageNumber": 46
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "1.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2016-10-26",
        "description": "Initial creation"
      },
      {
        "id": "ver_2",
        "versionNumber": "2.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-10-26",
        "description": "Correcting typos, cross-references, adding Echocardiographic Sub-study, and expanding AE interest for amputations.",
        "amendmentNumber": "Amendment 1"
      }
    ],
    "summary": {
      "referenceCount": 9,
      "annotationCount": 3,
      "versionCount": 2
    }
  }
}